Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Above 50 Day Moving Average of $5.73

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) shares passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $5.73 and traded as high as $6.78. Aurinia Pharmaceuticals shares last traded at $6.73, with a volume of 880,098 shares trading hands.

Analyst Ratings Changes

Separately, StockNews.com upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Aurinia Pharmaceuticals Price Performance

The company has a quick ratio of 5.05, a current ratio of 5.60 and a debt-to-equity ratio of 0.19. The company’s fifty day moving average is $5.73 and its 200 day moving average is $5.51. The firm has a market cap of $960.13 million, a price-to-earnings ratio of -15.65 and a beta of 1.44.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.01. Aurinia Pharmaceuticals had a negative return on equity of 11.75% and a negative net margin of 24.31%. The business had revenue of $57.10 million for the quarter, compared to the consensus estimate of $54.25 million. During the same quarter in the previous year, the business earned ($0.08) earnings per share. Aurinia Pharmaceuticals’s quarterly revenue was up 37.6% on a year-over-year basis. On average, equities research analysts predict that Aurinia Pharmaceuticals Inc. will post 0.15 EPS for the current year.

Insider Activity

In other news, insider Scott Michael Habig sold 18,249 shares of Aurinia Pharmaceuticals stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total value of $96,902.19. Following the completion of the transaction, the insider now owns 456,338 shares of the company’s stock, valued at approximately $2,423,154.78. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. HighMark Wealth Management LLC boosted its position in Aurinia Pharmaceuticals by 3.0% during the first quarter. HighMark Wealth Management LLC now owns 75,196 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 2,197 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Aurinia Pharmaceuticals by 9.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,634 shares of the biotechnology company’s stock worth $257,000 after buying an additional 2,390 shares during the period. ProShare Advisors LLC grew its stake in Aurinia Pharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 34,464 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 2,873 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in Aurinia Pharmaceuticals in the 4th quarter valued at about $30,000. Finally, Tidemark LLC acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter worth approximately $39,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.